229 related articles for article (PubMed ID: 19577545)
1. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.
Buccafusco JJ; Terry AV
Biochem Pharmacol; 2009 Oct; 78(7):852-62. PubMed ID: 19577545
[TBL] [Abstract][Full Text] [Related]
2. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
[TBL] [Abstract][Full Text] [Related]
3. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
[TBL] [Abstract][Full Text] [Related]
4. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Schneider JS; Tinker JP; Van Velson M; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
[TBL] [Abstract][Full Text] [Related]
6. Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.
Callahan PM; Terry AV; Tehim A
Psychopharmacology (Berl); 2014 Sep; 231(18):3695-706. PubMed ID: 24595504
[TBL] [Abstract][Full Text] [Related]
7. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R
Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875
[TBL] [Abstract][Full Text] [Related]
8. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
Freedman R
Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
[TBL] [Abstract][Full Text] [Related]
9. Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR
Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905
[TBL] [Abstract][Full Text] [Related]
10. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
Jones KM; McDonald IM; Bourin C; Olson RE; Bristow LJ; Easton A
Psychopharmacology (Berl); 2014 Feb; 231(4):673-83. PubMed ID: 24057763
[TBL] [Abstract][Full Text] [Related]
11. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
[TBL] [Abstract][Full Text] [Related]
12. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
13. Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys.
Terry AV; Plagenhoef M; Callahan PM
Psychopharmacology (Berl); 2016 Mar; 233(5):761-71. PubMed ID: 26612616
[TBL] [Abstract][Full Text] [Related]
14. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.
Buccafusco JJ; Terry AV; Decker MW; Gopalakrishnan M
Biochem Pharmacol; 2007 Oct; 74(8):1202-11. PubMed ID: 17706609
[TBL] [Abstract][Full Text] [Related]
15. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
[TBL] [Abstract][Full Text] [Related]
16. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor.
Chen L; Wang H; Zhang Z; Li Z; He D; Sokabe M; Chen L
J Neurosci Res; 2010 Jun; 88(8):1784-94. PubMed ID: 20127813
[TBL] [Abstract][Full Text] [Related]
17. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
Brown JW; Rueter LE; Zhang M
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
[TBL] [Abstract][Full Text] [Related]
18. Alpha 7 nicotinic acetylcholine receptor agonist GTS-21 mitigates isoflurane-induced cognitive impairment in aged rats.
Kong FJ; Ma LL; Zhang HH; Zhou JQ
J Surg Res; 2015 Mar; 194(1):255-61. PubMed ID: 25450597
[TBL] [Abstract][Full Text] [Related]
19. A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex.
Cloke JM; Nguyen R; Chung BY; Wasserman DI; De Lisio S; Kim JC; Bailey CD; Winters BD
J Neurosci; 2016 Dec; 36(50):12570-12585. PubMed ID: 27974613
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
